These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17950650)

  • 1. Effect of TNF antagonists on the T-lymphocyte response.
    Emilie D
    Joint Bone Spine; 2007 Dec; 74(6):558-9. PubMed ID: 17950650
    [No Abstract]   [Full Text] [Related]  

  • 2. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists.
    Hamdi H; Mariette X; Godot V; Weldingh K; Hamid AM; Prejean MV; Baron G; Lemann M; Puechal X; Breban M; Berenbaum F; Delchier JC; Flipo RM; Dautzenberg B; Salmon D; Humbert M; Emilie D;
    Arthritis Res Ther; 2006; 8(4):R114. PubMed ID: 16859506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma.
    Wallis RS
    J Investig Dermatol Symp Proc; 2007 May; 12(1):16-21. PubMed ID: 17502864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment.
    Dinarello CA
    J Rheumatol Suppl; 2005 Mar; 74():40-7. PubMed ID: 15742464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept.
    Weinberg JM; Bottino CJ; Lindholm J; Buchholz R
    J Drugs Dermatol; 2005; 4(5):544-55. PubMed ID: 16167412
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [What is the risk of malignancies associated with anti-TNF therapy?].
    Jonville-Béra AP; Lorette G
    Presse Med; 2009 Sep; 38(9):1209-10. PubMed ID: 19324517
    [No Abstract]   [Full Text] [Related]  

  • 7. [Efficacy and security of tumor necrosis factor antagonists in the treatment of rheumatoid arthritis].
    Pérez Pampín E; Gómez-Reino Carnota JJ
    Med Clin (Barc); 2008 Feb; 130(5):179-87. PubMed ID: 18341834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [TNF inhibitors for treatment of rheumatoid arthritis].
    Otomo K; Koike T
    Nihon Naika Gakkai Zasshi; 2008 Oct; 97(10):2405-12. PubMed ID: 19149036
    [No Abstract]   [Full Text] [Related]  

  • 9. The yin and yang of tumor necrosis factor inhibitors.
    Calabrese L
    Cleve Clin J Med; 2006 Mar; 73(3):251-6. PubMed ID: 16548447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic management of plaque psoriasis: the interest of anti-TNFalpha].
    Ortonne JP
    Ann Dermatol Venereol; 2005; 132(8-9 Pt 2):4S6-4S9. PubMed ID: 16335346
    [No Abstract]   [Full Text] [Related]  

  • 12. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.
    Markatseli TE; Alamanos Y; Saougou I; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2012; 30(1):31-8. PubMed ID: 22153557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycobacterium tuberculosis-induced cell death of primary human monocytes and macrophages is not significantly modulated by tumor necrosis factor-targeted biologicals.
    Reiling N; Schneider D; Ehlers S
    J Investig Dermatol Symp Proc; 2007 May; 12(1):26-33. PubMed ID: 17502866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential risk of tuberculosis reactivation among anti-TNF therapies is due to drug binding kinetics and permeability.
    Fallahi-Sichani M; Flynn JL; Linderman JJ; Kirschner DE
    J Immunol; 2012 Apr; 188(7):3169-78. PubMed ID: 22379032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity.
    Saliu OY; Sofer C; Stein DS; Schwander SK; Wallis RS
    J Infect Dis; 2006 Aug; 194(4):486-92. PubMed ID: 16845632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fungal infections complicating tumor necrosis factor alpha blockade therapy.
    Tsiodras S; Samonis G; Boumpas DT; Kontoyiannis DP
    Mayo Clin Proc; 2008 Feb; 83(2):181-94. PubMed ID: 18241628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
    Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
    Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R; Reich K
    Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A new clinical disease entity. Tuberculosis in users of TNF-alpha inhibitors].
    Trautmann M
    Pharm Unserer Zeit; 2012 Jan; 41(1):79-83. PubMed ID: 22470924
    [No Abstract]   [Full Text] [Related]  

  • 20. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.
    Lim LL; Fraunfelder FW; Rosenbaum JT
    Arthritis Rheum; 2007 Oct; 56(10):3248-52. PubMed ID: 17907169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.